Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#3645 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic neuroendocrine carcinomas (NEC) – A multicenter, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced NECs. Most NECs are hyper vascular, and the efficacy of paclitaxel-based combination regimens in the treatment of multiple digestive cancers has been reported.

Conference:

Presenting Author:

Authors: Zhang P, Li S, Li J, Lin S, Ming L,

Keywords: NEC, nab-paclitaxel, bevacizumab,

#3320 TGF-β increase caspase activation and migration in typical bronchial carcinoids

Introduction: Typical bronchial carcinoids (TBC) are well-differentiated neuroendocrine neoplasms (NEN) whose management can still be very challenging due to reduced sensitivity to therapy. Previous studies have reported TGF-β’s ability to activate mTOR pathway and induce epithelial to mesenchymal transition (EMT). Moreover, preliminary results show an overexpression of TGF-β signalling and caspase activation in TBC.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Gagliardi I

Authors: Borges de Souza P, Gagliardi I, Martelli M, Zatelli M,

Keywords: bronchial carcinoid, TGF-β signalling, mTOR, EMT,

#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report

Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Qi Z, Zhang Y, Li Y, Wang C, Wang X,

Keywords: neuroendocrine carcinoma, albumin-bound paclitaxe,